person · Reporting owner

RASTETTER WILLIAM H

Disclosed activity across 5 companies

Tapewire entity: 32781
SEC CIK: 0001205903

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Dare Bioscience, Inc.DARE · Entity 7799	Director	June 30, 2026	July 02, 2026
FATE THERAPEUTICS INCFATE · Entity 5968	Director	June 12, 2026	June 15, 2026
Iambic Therapeutics, Inc.IAM · Entity 184417	Director · Chairperson of the Board	October 14, 2026	October 14, 2026
NEUROCRINE BIOSCIENCES INCNBIX · Entity 2655	Director	May 27, 2026	May 29, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Dare Bioscience, Inc.

Report date June 30, 2026 · Filed July 02, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common stockSEC Table I · non-derivative	Direct	39,721	Reported balance After 2026-06-30 transaction · row 1 1 source row Row 1 · 2026-06-30 · Grant · Acquired 38,862 · Balance 39,721 F1: Represents shares underlying restricted stock units ("RSU") granted to the reporting person in lieu of cash compensation for service on the issuer's board of directors and its committees. Each RSU represents a contingent right to receive one share when vested. The RSUs vests on January 4, 2027.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares underlying restricted stock units ("RSU") granted to the reporting person in lieu of cash compensation for service on the issuer's board of directors and its committees. Each RSU represents a contingent right to receive one share when vested. The RSUs vests on January 4, 2027.

FATE THERAPEUTICS INC

Report date June 12, 2026 · Filed June 15, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.06 · Expires 2036-06-12	Direct	87,900	Reported balance After 2026-06-12 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-12 · Grant · Acquired 87,900 · Balance 87,900 F1: This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders. F2: The shares subject to this option shall vest and become exercisable on the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors.

Filing footnotes · ownership attribution and instrument terms

F1: This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders.

F2: The shares subject to this option shall vest and become exercisable on the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors.

Iambic Therapeutics, Inc.

Report date October 14, 2026 · Filed October 14, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Series B Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	Not disclosed	Reported balance Holding disclosure · report date 2026-10-14 · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · Balance Not disclosed F1: Each share of Series B Convertible Preferred Stock shall automatically convert into Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date. F2: The shares are held of record by the Rastetter Family Trust dated September 2, 2010, for which Dr. Rastetter serves as a trustee.
Series B-2 Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	Not disclosed	Reported balance Holding disclosure · report date 2026-10-14 · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · Balance Not disclosed F3: Each share of Series B-2 Convertible Preferred Stock shall automatically convert into Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date. F2: The shares are held of record by the Rastetter Family Trust dated September 2, 2010, for which Dr. Rastetter serves as a trustee.
Series B-3 Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	Not disclosed	Reported balance Holding disclosure · report date 2026-10-14 · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · Balance Not disclosed F4: Each share of Series B-3 Convertible Preferred Stock shall automatically convert into Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date. F2: The shares are held of record by the Rastetter Family Trust dated September 2, 2010, for which Dr. Rastetter serves as a trustee.
Series B-4 Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	Not disclosed	Reported balance Holding disclosure · report date 2026-10-14 · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · Balance Not disclosed F5: Each share of Series B-4 Convertible Preferred Stock shall automatically convert into Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date. F2: The shares are held of record by the Rastetter Family Trust dated September 2, 2010, for which Dr. Rastetter serves as a trustee.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.00 · Expires 2033-04-17	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-10-14 · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · Balance Not disclosed F6: Twenty-five percent of the shares subject to the option vested on March 9, 2024 and 1/48th of the shares vest monthly thereafter.
Convertible Promissory NotesSEC Table II · derivative / convertible security · Expires 2028-08-14	IndirectSee footnote	Not disclosed	Reported balance Holding disclosure · report date 2026-10-14 · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · Balance Not disclosed F8: The conversion price is equal to the lower of (i) 85% of the IPO Price (reflecting a 15% discount) and (ii) the price per share implied by a $900.0 million valuation cap. F7: The amount of shares reported assumes the Issuer's initial public offering price per share (the "IPO Price") to be $16.00 per share. F2: The shares are held of record by the Rastetter Family Trust dated September 2, 2010, for which Dr. Rastetter serves as a trustee.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of Series B Convertible Preferred Stock shall automatically convert into Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date.

F2: The shares are held of record by the Rastetter Family Trust dated September 2, 2010, for which Dr. Rastetter serves as a trustee.

F3: Each share of Series B-2 Convertible Preferred Stock shall automatically convert into Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date.

F4: Each share of Series B-3 Convertible Preferred Stock shall automatically convert into Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date.

F5: Each share of Series B-4 Convertible Preferred Stock shall automatically convert into Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date.

F6: Twenty-five percent of the shares subject to the option vested on March 9, 2024 and 1/48th of the shares vest monthly thereafter.

F7: The amount of shares reported assumes the Issuer's initial public offering price per share (the "IPO Price") to be $16.00 per share.

F8: The conversion price is equal to the lower of (i) 85% of the IPO Price (reflecting a 15% discount) and (ii) the price per share implied by a $900.0 million valuation cap.

NEUROCRINE BIOSCIENCES INC

Report date May 27, 2026 · Filed May 29, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Restriced Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	2,567	Reported balance After 2026-05-27 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-05-27 · Grant · Acquired 2,567 · Balance 2,567 F1: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2: The RSUs will vest in full on May 27, 2027.

Filing footnotes · ownership attribution and instrument terms

F1: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting.

F2: The RSUs will vest in full on May 27, 2027.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Regulus Therapeutics Inc.

Report date June 25, 2025 · Filed June 27, 2025

Section 16 reporting ended · disclosed 2025-06-27. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy The Rastetter Family Trust	57,292	Reported balance After 2025-06-25 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2025-06-25 · Other · Disposed 44,264 · Balance 57,292 F1: This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the "Merger Agreement"), by and among Regulus Therapeutics Inc. (the "Issuer"), Redwood Merger Sub Inc. ("Merger Sub"), a wholly owned, indirect subsidiary of Novartis AG ("Parent"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the "Shares"), in exchange for (a) $7.00 in cash per Share (the "Closing Amount"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a "CVR") per Share. F2: Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the "Offer Price"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. F3: Pursuant to the terms of the Merger Agreement, each Share was tendered in exchange for the Offer Price.
Common StockSEC Table I · non-derivative	IndirectBy The Rastetter Family Trust	0	Reported balance After 2025-06-25 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2025-06-25 · Disposition to issuer · Disposed 57,292 · Balance 0 F1: This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the "Merger Agreement"), by and among Regulus Therapeutics Inc. (the "Issuer"), Redwood Merger Sub Inc. ("Merger Sub"), a wholly owned, indirect subsidiary of Novartis AG ("Parent"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the "Shares"), in exchange for (a) $7.00 in cash per Share (the "Closing Amount"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a "CVR") per Share. F2: Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the "Offer Price"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. F4: Pursuant to terms of the Merger Agreement, each restricted stock unit that was subject to vesting or forfeiture conditions that was outstanding immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive (i) an amount in cash (without interest and subject to applicable withholding) equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such restricted stock unit immediately prior to the Effective Time by (B) the Closing Amount, plus (ii) one CVR with respect to each Share subject to such restricted stock unit immediately prior to the Effective Time.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $6.40	IndirectBy The Rastetter Family Trust	0	Reported balance After 2025-06-25 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2025-06-25 · Disposition to issuer · Disposed 4,650 · Balance 0 F1: This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the "Merger Agreement"), by and among Regulus Therapeutics Inc. (the "Issuer"), Redwood Merger Sub Inc. ("Merger Sub"), a wholly owned, indirect subsidiary of Novartis AG ("Parent"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the "Shares"), in exchange for (a) $7.00 in cash per Share (the "Closing Amount"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a "CVR") per Share. F2: Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the "Offer Price"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. F5: Pursuant to terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an "In-the-Money Option") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $8.80	IndirectBy The Rastetter Family Trust	0	Reported balance After 2025-06-25 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2025-06-25 · Disposition to issuer · Disposed 2,325 · Balance 0 F1: This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the "Merger Agreement"), by and among Regulus Therapeutics Inc. (the "Issuer"), Redwood Merger Sub Inc. ("Merger Sub"), a wholly owned, indirect subsidiary of Novartis AG ("Parent"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the "Shares"), in exchange for (a) $7.00 in cash per Share (the "Closing Amount"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a "CVR") per Share. F2: Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the "Offer Price"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. F6: Pursuant to terms of the Merger Agreement, each stock option that was outstanding and unexercised with a per Share exercise price equal to or greater than the Closing Amount but less than $14.00 (each, an "Out-of-the-Money Option") was automatically canceled and terminated and converted into the right to receive one CVR with respect to each Share subject to such Out-of-the-Money Option immediately prior to the Effective Time, and therefore may become entitled to receive, as of the date of the Milestone Payment (as defined in the Merger Agreement), an amount in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (i) the aggregate number of CVRs received in respect of such Out-of-the-Money Option by (ii) an amount equal to $14.00, less the per Share exercise price of such Out-of-the-Money Option (provided if no Milestone Payment is made, then no payments will be made with respect to any Out-of-the-Money Option).
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $9.90	IndirectBy The Rastetter Family Trust	0	Reported balance After 2025-06-25 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2025-06-25 · Disposition to issuer · Disposed 4,000 · Balance 0 F1: This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the "Merger Agreement"), by and among Regulus Therapeutics Inc. (the "Issuer"), Redwood Merger Sub Inc. ("Merger Sub"), a wholly owned, indirect subsidiary of Novartis AG ("Parent"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the "Shares"), in exchange for (a) $7.00 in cash per Share (the "Closing Amount"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a "CVR") per Share. F2: Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the "Offer Price"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. F6: Pursuant to terms of the Merger Agreement, each stock option that was outstanding and unexercised with a per Share exercise price equal to or greater than the Closing Amount but less than $14.00 (each, an "Out-of-the-Money Option") was automatically canceled and terminated and converted into the right to receive one CVR with respect to each Share subject to such Out-of-the-Money Option immediately prior to the Effective Time, and therefore may become entitled to receive, as of the date of the Milestone Payment (as defined in the Merger Agreement), an amount in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (i) the aggregate number of CVRs received in respect of such Out-of-the-Money Option by (ii) an amount equal to $14.00, less the per Share exercise price of such Out-of-the-Money Option (provided if no Milestone Payment is made, then no payments will be made with respect to any Out-of-the-Money Option).
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.70	IndirectBy The Rastetter Family Trust	0	Reported balance After 2025-06-25 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2025-06-25 · Disposition to issuer · Disposed 9,000 · Balance 0 F1: This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the "Merger Agreement"), by and among Regulus Therapeutics Inc. (the "Issuer"), Redwood Merger Sub Inc. ("Merger Sub"), a wholly owned, indirect subsidiary of Novartis AG ("Parent"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the "Shares"), in exchange for (a) $7.00 in cash per Share (the "Closing Amount"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a "CVR") per Share. F2: Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the "Offer Price"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. F5: Pursuant to terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an "In-the-Money Option") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.45	IndirectBy The Rastetter Family Trust	0	Reported balance After 2025-06-25 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2025-06-25 · Disposition to issuer · Disposed 30,000 · Balance 0 F1: This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the "Merger Agreement"), by and among Regulus Therapeutics Inc. (the "Issuer"), Redwood Merger Sub Inc. ("Merger Sub"), a wholly owned, indirect subsidiary of Novartis AG ("Parent"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the "Shares"), in exchange for (a) $7.00 in cash per Share (the "Closing Amount"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a "CVR") per Share. F2: Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the "Offer Price"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. F5: Pursuant to terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an "In-the-Money Option") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.36	IndirectBy The Rastetter Family Trust	0	Reported balance After 2025-06-25 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2025-06-25 · Disposition to issuer · Disposed 15,000 · Balance 0 F1: This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the "Merger Agreement"), by and among Regulus Therapeutics Inc. (the "Issuer"), Redwood Merger Sub Inc. ("Merger Sub"), a wholly owned, indirect subsidiary of Novartis AG ("Parent"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the "Shares"), in exchange for (a) $7.00 in cash per Share (the "Closing Amount"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a "CVR") per Share. F2: Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the "Offer Price"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. F5: Pursuant to terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an "In-the-Money Option") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.01	IndirectBy The Rastetter Family Trust	0	Reported balance After 2025-06-25 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2025-06-25 · Disposition to issuer · Disposed 30,000 · Balance 0 F1: This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the "Merger Agreement"), by and among Regulus Therapeutics Inc. (the "Issuer"), Redwood Merger Sub Inc. ("Merger Sub"), a wholly owned, indirect subsidiary of Novartis AG ("Parent"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the "Shares"), in exchange for (a) $7.00 in cash per Share (the "Closing Amount"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a "CVR") per Share. F2: Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the "Offer Price"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. F5: Pursuant to terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an "In-the-Money Option") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.01	IndirectBy The Rastetter Family Trust	0	Reported balance After 2025-06-25 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2025-06-25 · Disposition to issuer · Disposed 60,000 · Balance 0 F1: This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the "Merger Agreement"), by and among Regulus Therapeutics Inc. (the "Issuer"), Redwood Merger Sub Inc. ("Merger Sub"), a wholly owned, indirect subsidiary of Novartis AG ("Parent"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the "Shares"), in exchange for (a) $7.00 in cash per Share (the "Closing Amount"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a "CVR") per Share. F2: Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the "Offer Price"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. F5: Pursuant to terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an "In-the-Money Option") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the "Merger Agreement"), by and among Regulus Therapeutics Inc. (the "Issuer"), Redwood Merger Sub Inc. ("Merger Sub"), a wholly owned, indirect subsidiary of Novartis AG ("Parent"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the "Shares"), in exchange for (a) $7.00 in cash per Share (the "Closing Amount"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a "CVR") per Share.

F2: Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the "Offer Price"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.

F3: Pursuant to the terms of the Merger Agreement, each Share was tendered in exchange for the Offer Price.

F4: Pursuant to terms of the Merger Agreement, each restricted stock unit that was subject to vesting or forfeiture conditions that was outstanding immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive (i) an amount in cash (without interest and subject to applicable withholding) equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such restricted stock unit immediately prior to the Effective Time by (B) the Closing Amount, plus (ii) one CVR with respect to each Share subject to such restricted stock unit immediately prior to the Effective Time.

F5: Pursuant to terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an "In-the-Money Option") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time.

F6: Pursuant to terms of the Merger Agreement, each stock option that was outstanding and unexercised with a per Share exercise price equal to or greater than the Closing Amount but less than $14.00 (each, an "Out-of-the-Money Option") was automatically canceled and terminated and converted into the right to receive one CVR with respect to each Share subject to such Out-of-the-Money Option immediately prior to the Effective Time, and therefore may become entitled to receive, as of the date of the Milestone Payment (as defined in the Merger Agreement), an amount in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (i) the aggregate number of CVRs received in respect of such Out-of-the-Money Option by (ii) an amount equal to $14.00, less the per Share exercise price of such Out-of-the-Money Option (provided if no Milestone Payment is made, then no payments will be made with respect to any Out-of-the-Money Option).

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
April 19, 2023 Filed Apr 21, 2023 22:58 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	Exercise / conversionNon-Qualified Stock Option · Derivative	1,610	$12.71 Strike: $12.71	$20,463.10	Disclosure SEC source: 0001209191-23-025273 · doc4.xml · derivative · entry 5 RASTETTER WILLIAM H · CIK 0001205903 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,390 Underlying: Common Stock · 1,610 shares Expires 2023-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option was granted May 23, 2013 and vested in 12 equal monthly installments beginning June 23, 2013. Read SEC document
April 19, 2023 Filed Apr 21, 2023 22:58 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	SaleCommon Stock	903	$105.00	$94,818.61	Disclosure SEC source: 0001209191-23-025273 · doc4.xml · nonDerivative · entry 2 RASTETTER WILLIAM H · CIK 0001205903 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,729 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted on May 19, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $105.00 to $105.04. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
April 19, 2023 Filed Apr 21, 2023 22:58 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	Exercise / conversionCommon Stock	1,610	$12.71	$20,463.10	Disclosure SEC source: 0001209191-23-025273 · doc4.xml · nonDerivative · entry 1 RASTETTER WILLIAM H · CIK 0001205903 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,632 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 23, 2022 Filed Jun 24, 2022 20:52 UTC	Dare Bioscience, Inc. DARE · Entity 7799	GrantStock Option (right to buy) · Derivative	38,000	$0.00 Strike: $1.31	$0.00	Disclosure SEC source: 0001401914-22-000071 · wf-form4_165610393127419.xml · derivative · entry 1 RASTETTER WILLIAM H · CIK 0001205903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,000 Underlying: Common stock · 38,000 shares Expires 2032-06-23 F1 · derivative.exercise_date: This option will vest in full on the earlier of the first anniversary of the grant date or immediately prior to the issuer's first annual meeting of stockholders occurring after the grant date, subject to the director's continued service as a director, and will become exercisable in full upon a change in control of the issuer. Read SEC document
June 09, 2022 Filed Jun 10, 2022 20:17 UTC	Regulus Therapeutics Inc. RGLS · Entity 78034	GrantStock Option (Right to Buy) · Derivative	90,000	$0.00 Strike: $0.27	$0.00	Disclosure SEC source: 0001209191-22-035868 · doc4.xml · derivative · entry 1 RASTETTER WILLIAM H · CIK 0001205903 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · The Rastetter Family Trust Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2032-06-09 F1 · derivative.exercise_date: Pursuant to the Company's Non Employee Director's Compensation policy, the options are automatically granted on the date of the Company's Annual Meeting of Stockholders and will vest ratably over the following twelve months such that the option will be fully vested one year after the date of grant or on the date of the Company's next annual stockholder meeting, whichever occurs first, subject to the Reporting Person's continuous service. Read SEC document
June 09, 2022 Filed Jun 13, 2022 20:43 UTC	FATE THERAPEUTICS INC FATE · Entity 5968	GrantStock Option (Right to Buy) · Derivative	11,893	$0.00 Strike: $23.48	$0.00	Disclosure SEC source: 0001209191-22-036353 · doc4.xml · derivative · entry 4 RASTETTER WILLIAM H · CIK 0001205903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,893 Underlying: Common Stock · 11,893 shares Expires 2032-06-09 F4 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable on the earlier of (i) June 9, 2023 or (ii) the date of the Issuer's 2023 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors. Read SEC document
June 09, 2022 Filed Jun 13, 2022 20:43 UTC	FATE THERAPEUTICS INC FATE · Entity 5968	GrantCommon Stock	8,650	$0.00	$0.00	Disclosure SEC source: 0001209191-22-036353 · doc4.xml · nonDerivative · entry 1 RASTETTER WILLIAM H · CIK 0001205903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,331 F1 · security: Award of restricted stock units that vest in full on the earlier of (i) June 9, 2023 or (ii) the date of the Issuer's 2023 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors. Read SEC document
May 18, 2022 Filed May 20, 2022 20:14 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	GrantNon-Qualified Stock Option · Derivative	9,724	$0.00 Strike: $84.95	$0.00	Disclosure SEC source: 0001209191-22-030992 · doc4.xml · derivative · entry 1 RASTETTER WILLIAM H · CIK 0001205903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,724 Underlying: Common Stock · 9,724 shares Expires 2032-05-18 F1 · derivative.exercise_date: Option vests in 12 monthly installments beginning June 18, 2022. Read SEC document
April 01, 2022 Filed Apr 5, 2022 22:20 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	Exercise / conversionNon-Qualified Stock Option · Derivative	20,000	$6.66 Strike: $6.66	$133,200.00	Disclosure SEC source: 0001209191-22-023284 · doc4.xml · derivative · entry 3 RASTETTER WILLIAM H · CIK 0001205903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2022-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option was granted May 23, 2012 and vested in 12 equal monthly installments beginning June 23, 2012. Read SEC document
April 01, 2022 Filed Apr 5, 2022 22:20 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	SaleCommon Stock	10,728	$94.93	$1,018,366.13	Disclosure SEC source: 0001209191-22-023284 · doc4.xml · nonDerivative · entry 2 RASTETTER WILLIAM H · CIK 0001205903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,022 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $93.48 to $95.33. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
April 01, 2022 Filed Apr 5, 2022 22:20 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	Exercise / conversionCommon Stock	20,000	$6.66	$133,200.00	Disclosure SEC source: 0001209191-22-023284 · doc4.xml · nonDerivative · entry 1 RASTETTER WILLIAM H · CIK 0001205903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 24, 2021 Filed Jun 24, 2021 20:35 UTC	Dare Bioscience, Inc. DARE · Entity 7799	GrantStock Option (right to buy) · Derivative	30,000	$0.00 Strike: $1.46	$0.00	Disclosure SEC source: 0001401914-21-000090 · wf-form4_162456686646072.xml · derivative · entry 1 RASTETTER WILLIAM H · CIK 0001205903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common stock · 30,000 shares Expires 2031-06-24 F1 · derivative.exercise_date: This option will vest in full on the earlier of the first anniversary of the grant date or immediately prior to the issuer's first annual meeting of stockholders occurring after the grant date, subject to the director's continued service as a director, and will become exercisable in full upon a change in control of the issuer. Read SEC document
June 14, 2021 Filed Jun 15, 2021 20:44 UTC	Regulus Therapeutics Inc. RGLS · Entity 78034	GrantStock Option (Right to Buy) · Derivative	40,000	$0.00 Strike: $0.99	$0.00	Disclosure SEC source: 0001209191-21-040624 · doc4.xml · derivative · entry 1 RASTETTER WILLIAM H · CIK 0001205903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-06-13 F1 · derivative.exercise_date: Pursuant to the Company's Non Employee Director's Compensation policy, the options are automatically granted on the date of the Company's Annual Meeting of Stockholders and will vest ratably over the following twelve months such that the option will be fully vested one year after the date of grant or on the date of the Company's next annual stockholder meeting, whichever occurs first, subject to the Reporting Person's continuous service. Read SEC document
June 02, 2021 Filed Jun 4, 2021 21:30 UTC	FATE THERAPEUTICS INC FATE · Entity 5968	GrantStock Option (Right to Buy) · Derivative	4,334	$0.00 Strike: $68.94	$0.00	Disclosure SEC source: 0000899243-21-022086 · doc4.xml · derivative · entry 4 RASTETTER WILLIAM H · CIK 0001205903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,334 Underlying: Common Stock · 4,334 shares Expires 2031-06-01 F4 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable on the earlier of (i) June 2, 2022 or (ii) the date of the Issuer's 2022 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors. Read SEC document
June 02, 2021 Filed Jun 4, 2021 21:30 UTC	FATE THERAPEUTICS INC FATE · Entity 5968	GrantCommon Stock	2,681	$0.00	$0.00	Disclosure SEC source: 0000899243-21-022086 · doc4.xml · nonDerivative · entry 1 RASTETTER WILLIAM H · CIK 0001205903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,681 F1 · security: Award of restricted stock units that vest in full on the earlier of (i) June 2, 2022 or (ii) the date of the Issuer's 2022 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors. Read SEC document
May 19, 2021 Filed May 20, 2021 20:11 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	GrantNon-Qualified Stock Option · Derivative	8,833	$0.00 Strike: $92.35	$0.00	Disclosure SEC source: 0001209191-21-034392 · doc4.xml · derivative · entry 1 RASTETTER WILLIAM H · CIK 0001205903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,833 Underlying: Common Stock · 8,833 shares Expires 2031-05-19 F1 · derivative.exercise_date: Option vests in 12 equal monthly installments beginning June 19, 2021. Read SEC document
June 25, 2020 Filed Jun 27, 2020 00:56 UTC	Dare Bioscience, Inc. DARE · Entity 7799	GrantStock Option (right to buy) · Derivative	22,500	$0.00 Strike: $1.03	$0.00	Disclosure SEC source: 0001401914-20-000096 · wf-form4_159321935213925.xml · derivative · entry 1 RASTETTER WILLIAM H · CIK 0001205903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common stock · 22,500 shares Expires 2030-06-25 F1 · derivative.exercise_date: This option will vest in full on the earlier of the first anniversary of the grant date or immediately prior to the issuer's first annual meeting of stockholders occurring after the grant date, subject to the director's continued service as a director, and will become exercisable in full upon a change in control of the issuer. Read SEC document
June 17, 2020 Filed Jun 19, 2020 20:42 UTC	Regulus Therapeutics Inc. RGLS · Entity 78034	GrantStock Option (Right to Buy) · Derivative	23,250	$0.00 Strike: $0.88	$0.00	Disclosure SEC source: 0001209191-20-037957 · doc4.xml · derivative · entry 1 RASTETTER WILLIAM H · CIK 0001205903 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · THE RASTETTER FAMILY TRUST DTD 9-2-2010 Disclosed balance after: 23,250 Underlying: Common Stock · 23,250 shares Expires 2030-06-16 F1 · derivative.exercise_date: Pursuant to the Company's Non Employee Director's Compensation policy, the options are automatically granted on the date of the Company's Annual Meeting of Stockholders and will vest ratably over the following twelve months such that the option will be fully vested one year after the date of grant or on the date of the Company's next annual stockholder meeting, whichever occurs first, subject to the Reporting Person's continuous service. Read SEC document
May 19, 2020 Filed May 21, 2020 22:42 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	GrantNon-Qualified Stock Option · Derivative	6,018	$0.00 Strike: $119.93	$0.00	Disclosure SEC source: 0001209191-20-031463 · doc4.xml · derivative · entry 1 RASTETTER WILLIAM H · CIK 0001205903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,018 Underlying: Common Stock · 6,018 shares Expires 2030-05-19 F1 · derivative.exercise_date: Option vests in 12 equal monthly installments beginning June 19, 2020. Read SEC document
May 01, 2020 Filed May 5, 2020 20:19 UTC	FATE THERAPEUTICS INC FATE · Entity 5968	GrantStock Option (right to buy) · Derivative	16,000	Not disclosed Strike: $26.59	Not disclosed	Disclosure SEC source: 0001209191-20-027107 · doc4.xml · derivative · entry 1 RASTETTER WILLIAM H · CIK 0001205903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2030-05-01 F2 · price: Not applicable. F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable on the earlier of (i) May 1, 2021 or (ii) the date of the Issuer's 2021 Annual Meeting of Stockholders, subject to the recipient's continued service on the Issuer's Board of Directors. Read SEC document
March 30, 2020 Filed Mar 31, 2020 20:01 UTC	FATE THERAPEUTICS INC FATE · Entity 5968	Exercise / conversionStock Option (right to buy) · Derivative	28,461	Not disclosed Strike: $1.37	Not disclosed	Disclosure SEC source: 0001209191-20-021788 · doc4.xml · derivative · entry 2 RASTETTER WILLIAM H · CIK 0001205903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28,461 shares Expires 2023-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Not applicable. F1 · derivative.exercise_date: This option is fully vested. Read SEC document
March 30, 2020 Filed Mar 31, 2020 20:01 UTC	FATE THERAPEUTICS INC FATE · Entity 5968	Exercise / conversionCommon stock	28,461	$1.37	$38,991.57	Disclosure SEC source: 0001209191-20-021788 · doc4.xml · nonDerivative · entry 1 RASTETTER WILLIAM H · CIK 0001205903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,461 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 30, 2020 Filed Apr 2, 2021 20:24 UTC Amendment	FATE THERAPEUTICS INC FATE · Entity 5968	GiftCommon Stock	28,461	$0.00	$0.00	Disclosure SEC source: 0000899243-21-014588 · doc4a.xml · nonDerivative · entry 2 RASTETTER WILLIAM H · CIK 0001205903 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By The Rastetter Family Trust, dated 09/02/10 Disclosed balance after: 146,821 F1 · ownership.nature: These shares are owned of record by The Investment 2002 Trust, dated November 11, 2002 for which William H. Rastetter is the sole trustee and owner. Read SEC document
March 30, 2020 Filed Apr 2, 2021 20:24 UTC Amendment	FATE THERAPEUTICS INC FATE · Entity 5968	GiftCommon Stock	28,461	$0.00	$0.00	Disclosure SEC source: 0000899243-21-014588 · doc4a.xml · nonDerivative · entry 1 RASTETTER WILLIAM H · CIK 0001205903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document
February 03, 2020 Filed Feb 4, 2020 22:05 UTC	Regulus Therapeutics Inc. RGLS · Entity 78034	ConversionClass A-2 Convertible Preferred Stock · Derivative	22,594	$0.00	$0.00	Disclosure SEC source: 0001209191-20-006435 · doc4.xml · derivative · entry 2 RASTETTER WILLIAM H · CIK 0001205903 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · The Rastetter Family Trust dtd 9-2-2010 Disclosed balance after: 0 Underlying: Common Stock · 225,940 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Class A-2 Convertible Preferred have no expiration date and are convertible at any time at the election of the holder into shares of Common Stock without payment of further consideration. Each share of Class A-2 Convertible Preferred Stock converts into 10 shares of Common Stock. F1 · derivative.exercise_date: The shares of Class A-2 Convertible Preferred have no expiration date and are convertible at any time at the election of the holder into shares of Common Stock without payment of further consideration. Each share of Class A-2 Convertible Preferred Stock converts into 10 shares of Common Stock. F1 · derivative.expiration_date: The shares of Class A-2 Convertible Preferred have no expiration date and are convertible at any time at the election of the holder into shares of Common Stock without payment of further consideration. Each share of Class A-2 Convertible Preferred Stock converts into 10 shares of Common Stock. Read SEC document
February 03, 2020 Filed Feb 4, 2020 22:05 UTC	Regulus Therapeutics Inc. RGLS · Entity 78034	ConversionCommon Stock	225,940	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-006435 · doc4.xml · nonDerivative · entry 1 RASTETTER WILLIAM H · CIK 0001205903 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · The Rastetter Family Trust dtd 9-2-2010 Disclosed balance after: 390,584 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of Class A-2 Convertible Preferred have no expiration date and are convertible at any time at the election of the holder into shares of Common Stock without payment of further consideration. Each share of Class A-2 Convertible Preferred Stock converts into 10 shares of Common Stock. Read SEC document
December 24, 2019 Filed Dec 26, 2019 13:52 UTC	Regulus Therapeutics Inc. RGLS · Entity 78034	GrantCommon Stock Purchase Warrant (Right to Buy) · Derivative	225,940	$0.13 Strike: $0.67	$28,242.50	Disclosure SEC source: 0001209191-19-061856 · doc4.xml · derivative · entry 2 RASTETTER WILLIAM H · CIK 0001205903 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · THE RASTETTER FAMILY TRUST DTD 9-2-2010 Disclosed balance after: 225,940 Underlying: Common Stock · 225,940 shares Expires 2024-12-24 F2 · kind: The securities were acquired from the issuer pursuant to a Securities Purchase Agreement dated May 3, 2019. The Securities Purchase Agreement and the issuance of the securities thereunder were approved by the Issuer's Board of Directors and an independent committee thereof. Read SEC document
December 24, 2019 Filed Dec 26, 2019 13:52 UTC	Regulus Therapeutics Inc. RGLS · Entity 78034	GrantClass A-2 Convertible Preferred Stock · Derivative	22,594	$6.66	$150,476.04	Disclosure SEC source: 0001209191-19-061856 · doc4.xml · derivative · entry 1 RASTETTER WILLIAM H · CIK 0001205903 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · THE RASTETTER FAMILY TRUST DTD 9-2-2010 Disclosed balance after: 22,594 Underlying: Common Stock · 225,940 shares Expires not disclosed F1 · derivative.exercise_price: The shares of Class A-2 Convertible Preferred Stock have no expiration date and are convertible at any time at the election of the holder into shares of Common Stock without payment of further consideration. Each share of Class A-2 Convertible Preferred Stock converts into 10 shares of Common Stock. F2 · kind: The securities were acquired from the issuer pursuant to a Securities Purchase Agreement dated May 3, 2019. The Securities Purchase Agreement and the issuance of the securities thereunder were approved by the Issuer's Board of Directors and an independent committee thereof. F1 · derivative.exercise_date: The shares of Class A-2 Convertible Preferred Stock have no expiration date and are convertible at any time at the election of the holder into shares of Common Stock without payment of further consideration. Each share of Class A-2 Convertible Preferred Stock converts into 10 shares of Common Stock. F1 · derivative.expiration_date: The shares of Class A-2 Convertible Preferred Stock have no expiration date and are convertible at any time at the election of the holder into shares of Common Stock without payment of further consideration. Each share of Class A-2 Convertible Preferred Stock converts into 10 shares of Common Stock. Read SEC document
October 10, 2019 Filed Oct 15, 2019 20:46 UTC	Regulus Therapeutics Inc. RGLS · Entity 78034	GrantStock Option (Right to Buy) · Derivative	46,500	$0.00 Strike: $0.64	$0.00	Disclosure SEC source: 0001209191-19-053168 · doc4.xml · derivative · entry 1 RASTETTER WILLIAM H · CIK 0001205903 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · THE RASTETTER FAMILY TRUST DTD 9-2-2010 Disclosed balance after: 46,500 Underlying: Common Stock · 46,500 shares Expires 2029-10-09 F1 · derivative.exercise_date: The options will vest ratably over the following twelve months such that the option will be fully vested one year after the date of grant or on the date of the Company's next annual shareholder meeting, whichever occurs first, subject to the Reporting Person's continuous service. Read SEC document
June 13, 2019 Filed Jun 14, 2019 18:33 UTC	Dare Bioscience, Inc. DARE · Entity 7799	GrantStock Option (right to buy) · Derivative	22,500	$0.00 Strike: $0.90	$0.00	Disclosure SEC source: 0001401914-19-000064 · wf-form4_156053719512628.xml · derivative · entry 1 RASTETTER WILLIAM H · CIK 0001205903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common stock · 22,500 shares Expires 2029-06-13 F1 · derivative.exercise_date: This option will vest in full on the earlier of the first anniversary of the grant date or immediately prior to the issuer's first annual meeting of stockholders occurring after the grant date, subject to the director's continued service as a director, and will become exercisable in full upon a change in control of the issuer. Read SEC document
May 22, 2019 Filed May 23, 2019 21:53 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	GrantNon-Qualified Stock Option · Derivative	13,000	$0.00 Strike: $79.79	$0.00	Disclosure SEC source: 0001209191-19-032407 · doc4.xml · derivative · entry 1 RASTETTER WILLIAM H · CIK 0001205903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires 2029-05-22 F1 · derivative.exercise_date: Option vests in 12 equal monthly installments beginning June 22, 2019. Read SEC document
May 07, 2019 Filed May 8, 2019 21:14 UTC	Regulus Therapeutics Inc. RGLS · Entity 78034	PurchaseCommon Stock Purchase Warrant (Right to Buy) · Derivative	92,889	$0.13 Strike: $1.08	$11,611.13	Disclosure SEC source: 0001209191-19-028277 · doc4.xml · derivative · entry 2 RASTETTER WILLIAM H · CIK 0001205903 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · THE RASTETTER FAMILY TRUST DTD 09-02-2010 Disclosed balance after: 92,889 Underlying: Common Stock · 92,889 shares Expires 2024-05-07 Read SEC document
May 07, 2019 Filed May 8, 2019 21:14 UTC	Regulus Therapeutics Inc. RGLS · Entity 78034	PurchaseCommon Stock	92,889	$1.08	$100,320.12	Disclosure SEC source: 0001209191-19-028277 · doc4.xml · nonDerivative · entry 1 RASTETTER WILLIAM H · CIK 0001205903 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · THE RASTETTER FAMILY TRUST DTD 9-2-2010 Disclosed balance after: 154,223 Read SEC document
May 07, 2019 Filed May 21, 2019 20:45 UTC Amendment	Regulus Therapeutics Inc. RGLS · Entity 78034	GrantCommon Stock Purchase Warrant (Right to Buy) · Derivative	92,889	$0.13 Strike: $1.08	$11,611.13	Disclosure SEC source: 0001209191-19-031766 · doc4a.xml · derivative · entry 2 RASTETTER WILLIAM H · CIK 0001205903 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · The Rastetter Family Trust DTD 9-2-2010 Disclosed balance after: 92,889 Underlying: Common Stock · 92,889 shares Expires 2024-05-07 F1 · kind: This Form 4 is being amended to correct the transaction code. The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated May 3, 2019 with a closing date of May 7, 2019. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by the Issuer's Board of Directors and an independent committee thereof. Read SEC document
May 07, 2019 Filed May 21, 2019 20:45 UTC Amendment	Regulus Therapeutics Inc. RGLS · Entity 78034	GrantCommon Stock	92,889	$1.08	$100,320.12	Disclosure SEC source: 0001209191-19-031766 · doc4a.xml · nonDerivative · entry 1 RASTETTER WILLIAM H · CIK 0001205903 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · The Rastetter Family Trust DTD 9-2-2010 Disclosed balance after: 154,223 F1 · kind: This Form 4 is being amended to correct the transaction code. The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated May 3, 2019 with a closing date of May 7, 2019. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by the Issuer's Board of Directors and an independent committee thereof. Read SEC document
May 03, 2019 Filed May 7, 2019 20:07 UTC	FATE THERAPEUTICS INC FATE · Entity 5968	GrantStock Option (right to buy) · Derivative	16,000	Not disclosed Strike: $17.15	Not disclosed	Disclosure SEC source: 0001209191-19-027952 · doc4.xml · derivative · entry 1 RASTETTER WILLIAM H · CIK 0001205903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2029-05-03 F2 · price: Not applicable. F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable on the earlier of (i) May 3, 2020 or (ii) the date of the Issuer's 2020 Annual Meeting of Stockholders, subject to the recipient's continued service on the Issuer's Board of Directors. Read SEC document
November 12, 2018 Filed Nov 13, 2018 22:33 UTC	Regulus Therapeutics Inc. RGLS · Entity 78034	Disposition to issuerStock Option (Right to Buy) · Derivative	4,583	Not disclosed Strike: $8.76	Not disclosed	Disclosure SEC source: 0001209191-18-058344 · doc4.xml · derivative · entry 9 RASTETTER WILLIAM H · CIK 0001205903 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · William H. Rastetter TTEE, Marisa Rastetter TTEE 9-2-2010 FBO Rastetter Family Trus Disclosed balance after: 0 Underlying: Common Stock · 4,583 shares Expires 2028-05-31 F2 · shares: Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018. F4 · price: On November 12, 2018, the issuer cancelled, pursuant to the issuer's option exchange program, the listed option. In exchange for the options cancelled, the reporting person received the Restricted Stock Units reported above in Table I. F6 · derivative.exercise_date: The cancelled option vested in twelve equally monthly installments, such that the option would have been fully vested one year from the date of grant, or the date of the Company's next annual shareholder meeting, whichever occured first. F2 · derivative.underlying_shares: Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018. Read SEC document
November 12, 2018 Filed Nov 13, 2018 22:33 UTC	Regulus Therapeutics Inc. RGLS · Entity 78034	Disposition to issuerStock Option (Right to Buy) · Derivative	6,250	Not disclosed Strike: $8.52	Not disclosed	Disclosure SEC source: 0001209191-18-058344 · doc4.xml · derivative · entry 8 RASTETTER WILLIAM H · CIK 0001205903 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · William H. Rastetter TTEE, Marisa Rastetter TTEE 9-2-2010 FBO Rastetter Family Trus Disclosed balance after: 0 Underlying: Common Stock · 6,250 shares Expires 2028-05-16 F2 · shares: Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018. F4 · price: On November 12, 2018, the issuer cancelled, pursuant to the issuer's option exchange program, the listed option. In exchange for the options cancelled, the reporting person received the Restricted Stock Units reported above in Table I. F5 · derivative.exercise_date: The cancelled option provided for vesting in 12 equal monthly installments commencing on the date of grant. F2 · derivative.underlying_shares: Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018. Read SEC document
November 12, 2018 Filed Nov 13, 2018 22:33 UTC	Regulus Therapeutics Inc. RGLS · Entity 78034	Disposition to issuerStock Option (Right to Buy) · Derivative	2,500	Not disclosed Strike: $17.40	Not disclosed	Disclosure SEC source: 0001209191-18-058344 · doc4.xml · derivative · entry 7 RASTETTER WILLIAM H · CIK 0001205903 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · William H. Rastetter TTEE, Marisa Rastetter TTEE 9-2-2010 FBO Rastetter Family Trus Disclosed balance after: 0 Underlying: Common Stock · 2,500 shares Expires 2027-05-30 F2 · shares: Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018. F4 · price: On November 12, 2018, the issuer cancelled, pursuant to the issuer's option exchange program, the listed option. In exchange for the options cancelled, the reporting person received the Restricted Stock Units reported above in Table I. F3 · derivative.exercise_date: The shares subject to the cancelled option were fully vested. F2 · derivative.underlying_shares: Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018. Read SEC document
November 12, 2018 Filed Nov 13, 2018 22:33 UTC	Regulus Therapeutics Inc. RGLS · Entity 78034	Disposition to issuerStock Option (Right to Buy) · Derivative	3,051	Not disclosed Strike: $74.40	Not disclosed	Disclosure SEC source: 0001209191-18-058344 · doc4.xml · derivative · entry 6 RASTETTER WILLIAM H · CIK 0001205903 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · William H. Rastetter TTEE, Marisa Rastetter TTEE 9-2-2010 FBO Rastetter Family Trus Disclosed balance after: 0 Underlying: Common Stock · 3,051 shares Expires 2026-05-31 F2 · shares: Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018. F4 · price: On November 12, 2018, the issuer cancelled, pursuant to the issuer's option exchange program, the listed option. In exchange for the options cancelled, the reporting person received the Restricted Stock Units reported above in Table I. F3 · derivative.exercise_date: The shares subject to the cancelled option were fully vested. F2 · derivative.underlying_shares: Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018. Read SEC document
November 12, 2018 Filed Nov 13, 2018 22:33 UTC	Regulus Therapeutics Inc. RGLS · Entity 78034	Disposition to issuerStock Option (Right to Buy) · Derivative	1,458	Not disclosed Strike: $120.24	Not disclosed	Disclosure SEC source: 0001209191-18-058344 · doc4.xml · derivative · entry 5 RASTETTER WILLIAM H · CIK 0001205903 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · William H. Rastetter TTEE, Marisa Rastetter TTEE 9-2-2010 FBO Rastetter Family Trus Disclosed balance after: 0 Underlying: Common Stock · 1,458 shares Expires 2025-06-08 F2 · shares: Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018. F4 · price: On November 12, 2018, the issuer cancelled, pursuant to the issuer's option exchange program, the listed option. In exchange for the options cancelled, the reporting person received the Restricted Stock Units reported above in Table I. F3 · derivative.exercise_date: The shares subject to the cancelled option were fully vested. F2 · derivative.underlying_shares: Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018. Read SEC document
November 12, 2018 Filed Nov 13, 2018 22:33 UTC	Regulus Therapeutics Inc. RGLS · Entity 78034	Disposition to issuerStock Option (Right to Buy) · Derivative	1,458	Not disclosed Strike: $74.64	Not disclosed	Disclosure SEC source: 0001209191-18-058344 · doc4.xml · derivative · entry 4 RASTETTER WILLIAM H · CIK 0001205903 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · William H. Rastetter TTEE, Marisa Rastetter TTEE 9-2-2010 FBO Rastetter Family Trus Disclosed balance after: 0 Underlying: Common Stock · 1,458 shares Expires 2024-05-21 F2 · shares: Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018. F4 · price: On November 12, 2018, the issuer cancelled, pursuant to the issuer's option exchange program, the listed option. In exchange for the options cancelled, the reporting person received the Restricted Stock Units reported above in Table I. F3 · derivative.exercise_date: The shares subject to the cancelled option were fully vested. F2 · derivative.underlying_shares: Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018. Read SEC document
November 12, 2018 Filed Nov 13, 2018 22:33 UTC	Regulus Therapeutics Inc. RGLS · Entity 78034	Disposition to issuerStock Option (Right to Buy) · Derivative	1,458	Not disclosed Strike: $111.84	Not disclosed	Disclosure SEC source: 0001209191-18-058344 · doc4.xml · derivative · entry 3 RASTETTER WILLIAM H · CIK 0001205903 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · William H. Rastetter TTEE, Marisa Rastetter TTEE 9-2-2010 FBO Rastetter Family Trus Disclosed balance after: 0 Underlying: Common Stock · 1,458 shares Expires 2023-06-09 F2 · shares: Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018. F4 · price: On November 12, 2018, the issuer cancelled, pursuant to the issuer's option exchange program, the listed option. In exchange for the options cancelled, the reporting person received the Restricted Stock Units reported above in Table I. F3 · derivative.exercise_date: The shares subject to the cancelled option were fully vested. F2 · derivative.underlying_shares: Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018. Read SEC document
November 12, 2018 Filed Nov 13, 2018 22:33 UTC	Regulus Therapeutics Inc. RGLS · Entity 78034	Disposition to issuerStock Option (Right to Buy) · Derivative	2,500	Not disclosed Strike: $92.04	Not disclosed	Disclosure SEC source: 0001209191-18-058344 · doc4.xml · derivative · entry 2 RASTETTER WILLIAM H · CIK 0001205903 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · William H. Rastetter TTEE, Marisa Rastetter TTEE 9-2-2010 FBO Rastetter Family Trus Disclosed balance after: 0 Underlying: Common Stock · 2,500 shares Expires 2023-03-31 F2 · shares: Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018. F4 · price: On November 12, 2018, the issuer cancelled, pursuant to the issuer's option exchange program, the listed option. In exchange for the options cancelled, the reporting person received the Restricted Stock Units reported above in Table I. F3 · derivative.exercise_date: The shares subject to the cancelled option were fully vested. F2 · derivative.underlying_shares: Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018. Read SEC document
November 12, 2018 Filed Nov 13, 2018 22:33 UTC	Regulus Therapeutics Inc. RGLS · Entity 78034	GrantCommon Stock	23,258	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-058344 · doc4.xml · nonDerivative · entry 1 RASTETTER WILLIAM H · CIK 0001205903 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · William H. Rastetter TTEE, Marisa Rastetter TTEE 9-2-2010 FBO Rastetter Family Trust Disclosed balance after: 79,672 F1 · price: On November 12, 2018, the issuer canceled, pursuant to the issuer's option exchange program, the options listed below in Table II. In exchange for the options cancelled, the reporting person received Restricted Stock Units (RSUs) as reported in this Table I. The RSUs vest ratably on a quarterly basis, such that the the RSUs are fully vested one year after the date of grant, subject to the reporting person's continuous service to Regulus through each vesting date. F2 · balance_after: Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018. Read SEC document
July 10, 2018 Filed Jul 11, 2018 21:45 UTC	Dare Bioscience, Inc. DARE · Entity 7799	GrantStock Option (right to buy) · Derivative	45,000	$0.00 Strike: $1.35	$0.00	Disclosure SEC source: 0001209191-18-042385 · doc4.xml · derivative · entry 1 RASTETTER WILLIAM H · CIK 0001205903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2028-07-10 F1 · derivative.exercise_date: This option vests as to 1/3rd of the shares subject to this option on each of July 10, 2019, 2020 and 2021, subject to the reporting person's continued service to the issuer, and will become exercisable in full upon a change of control of the issuer. Read SEC document
June 01, 2018 Filed Jun 5, 2018 20:30 UTC	Regulus Therapeutics Inc. RGLS · Entity 78034	GrantStock Option (Right to Buy) · Derivative	55,000	$0.00 Strike: $0.73	$0.00	Disclosure SEC source: 0001209191-18-035702 · doc4.xml · derivative · entry 1 RASTETTER WILLIAM H · CIK 0001205903 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Rastetter Family Trust dated 9-2-2010 Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2028-05-31 F1 · derivative.exercise_date: The option will vest in twelve equally monthly installments, such that the option will be fully vested one year from the date of grant, or the date of the Company's 2019 annual shareholder meeting, whichever occurs first. Read SEC document
May 24, 2018 Filed May 26, 2018 00:03 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	GrantNon-Qualified Stock Option · Derivative	15,000	$0.00 Strike: $94.64	$0.00	Disclosure SEC source: 0001209191-18-033635 · doc4.xml · derivative · entry 1 RASTETTER WILLIAM H · CIK 0001205903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-05-24 F1 · derivative.exercise_date: Option vests in 12 equal monthly installments beginning June 24, 2018. Read SEC document
May 17, 2018 Filed May 21, 2018 20:42 UTC	Regulus Therapeutics Inc. RGLS · Entity 78034	GrantStock Option (Right to Buy) · Derivative	75,000	$0.00 Strike: $0.71	$0.00	Disclosure SEC source: 0001209191-18-031895 · doc4.xml · derivative · entry 1 RASTETTER WILLIAM H · CIK 0001205903 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Rastetter Family Trust dated 9-2-2010 Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2028-05-17 F1 · derivative.exercise_date: The option will vest in twelve equally monthly installments, such that the option will be fully vested one year from the date of grant, or the date of the Company's 2019 annual shareholder meeting, whichever occurs first. Read SEC document
May 02, 2018 Filed May 4, 2018 20:20 UTC	FATE THERAPEUTICS INC FATE · Entity 5968	GrantStock Option (right to buy) · Derivative	16,000	Not disclosed Strike: $9.78	Not disclosed	Disclosure SEC source: 0001209191-18-028109 · doc4.xml · derivative · entry 1 RASTETTER WILLIAM H · CIK 0001205903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2028-05-02 F2 · price: Not applicable. F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable on the earlier of (i) May 2, 2019 or (ii) the date of the 2019 Annual Meeting of Stockholders, subject to the recipient's continued service on the Issuer's Board of Directors. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.